NASDAQ:PAND Pandion Therapeutics (PAND) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free PAND Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$60.05▼$60.0550-Day Range$59.90▼$60.2852-Week Range$10.28▼$62.90VolumeN/AAverage Volume355,921 shsMarket Capitalization$1.77 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Pandion Therapeutics alerts: Email Address Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Pandion Therapeutics Stock (NASDAQ:PAND)Pandion Therapeutics, Inc., a clinical stage biopharmaceutical company, develops various therapeutics to address the unmet needs of patients suffering from autoimmune diseases. Its lead product candidate is PT101, an effector module comprising an engineered variant of wild-type interleukin-2 (IL-2) fused to a protein backbone that is in Phase 1a clinical trials for the treatment of various autoimmune and inflammatory diseases. The company's other product candidates comprise PT627, a systemic PD-1 agonist that is in preclinical studies for the treatment of autoimmune diseases; PT001, a bifunctional molecule combining its PD-1 agonist effector with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM) to drive tissue-selective immunomodulation in the gastrointestinal tract; and PT002, a tethered bifunctional molecule that utilizes its IL-2 mutein effector module coupled with a MAdCAM-tether module to deliver the IL-2 mutein effector to the gastrointestinal tract where MAdCAM is expressed. It has a license and collaboration agreement with Astellas Pharma Inc. to discover and develop novel compounds for autoimmune diseases of the pancreas, including type 1 diabetes. The company was formerly known as Immunotolerance, Inc. and changed its name to Pandion Therapeutics, Inc. in June 2017. Pandion Therapeutics, Inc. was incorporated in 2016 and is headquartered in Watertown, Massachusetts.Read More Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here PAND Stock News HeadlinesMarch 13, 2024 | bloomberg.comEx-FBI Trainee Gets 15 Months for Trading on Girlfriend’s InfoFebruary 2, 2024 | finanznachrichten.deMallinckrodt plc: Mallinckrodt Announces Board of Directors and Leadership UpdatesApril 25, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”January 4, 2024 | bizjournals.comVC funding update: Which Boston-area startups raised money in December?December 12, 2023 | bizjournals.comFormer Pandion exec's new startup launches with $213M for gene-editingDecember 4, 2023 | bizjournals.comBiogen vet's new startup raises nine-figure round, moves to WatertownNovember 1, 2023 | morningstar.comAptevo Therapeutics Inc APVOSeptember 19, 2023 | bizjournals.comFormer Fox Chase Cancer Center leader and current Wistar CEO target $10M for new ventureApril 25, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”June 10, 2023 | thestreet.comSarepta Therapeutics FDA Panel Live BlogJanuary 11, 2023 | benzinga.comAgile Therapeutics Stock (NASDAQ:AGRX), Quotes and News SummaryNovember 22, 2022 | bizjournals.comGet to know the BostInno Fire Awards life sciences honoreesNovember 21, 2022 | finance.yahoo.comCybrexa Therapeutics Presents Findings from First-in-Human Study of CBX-12 as a Plenary Oral Presentation at 34th EORTC-NCI-AACR SymposiumOctober 24, 2022 | bizjournals.comTour the latest co-laboratory space in LabCentral's networkOctober 5, 2022 | bizjournals.comJo Viney aims to be 'proactive and decisive' in allocating her timeSeptember 20, 2022 | stockhouse.comOptimus Healthcare Services, Inc. Appoints John P. Sganga Chair of the Board of Directors and Chief Executive Officer of OptimusAugust 21, 2022 | seekingalpha.comSelecta Biosciences: A Derivative Play On Gene Therapies Via ImmTOR PlatformAugust 17, 2022 | finance.yahoo.comSonoma Biotherapeutics Expands Board of Directors with Appointments of Katina Dorton, J.D., MBA, and John Davis, M.D., MPHJuly 25, 2022 | afr.comEx-Goldman banker tipped squash buddy on deals, US allegesJuly 25, 2022 | msn.comEx-U.S.congressman among 9 accused of insider tradingJuly 25, 2022 | seekingalpha.comSEC charges 10 people with insider trading in four cases (update)July 25, 2022 | msn.comFormer congressman among nine charged with insider tradingJuly 25, 2022 | reuters.comProsecutors say FBI trainee stole tips from lawyer-girlfriend to trade on Merck dealJuly 25, 2022 | nypost.comEx-Congressman Stephen Buyer, FBI trainee indicted for insider tradingJuly 25, 2022 | msn.comInvestment banker, ex-FBI trainee charged with insider tradingMay 25, 2022 | bizjournals.comMerck to hire another 100 at newly expanded Cambridge research labMay 2, 2022 | finance.yahoo.comVentus Therapeutics Appoints Stuart Green, M.D., as Chief Medical OfficerSee More Headlines Receive PAND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pandion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/16/2020Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:PAND CUSIPN/A CIKN/A Webwww.pandiontx.com Phone617-393-5925FaxN/AEmployees56Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$970,000.00 Price / Sales1,827.25 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares29,516,000Free FloatN/AMarket Cap$1.77 billion OptionableNot Optionable BetaN/A Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Rahul Kakkar (Age 46)CEO & Director Comp: $483.67kDr. Joanne L. Viney Ph.D. (Age 55)Pres & Chief Scientific Officer Comp: $543.01kMr. Vikas Goyal (Age 42)Sr. VP of Bus. Devel. Comp: $146.25kMr. Eric D. Larson (Age 51)VP of Fin. Mr. Edward D. Freedman J.D. (Age 52)Esq., Chief Operating Officer Mr. Anthony MullinVP of HRDr. John S. Sundy M.D. (Age 59)Ph.D., Chief Medical Officer Mr. Nathan Higginson-Scott Ph.D.VP of Research & Head of BiotherapeuticsMr. Kevin Otipoby Ph.D.VP of Research & Head of ImmunologyMs. Kata Kis-Toth Ph.D.Director & Head of Translational SciencesMore ExecutivesKey CompetitorsSyndax PharmaceuticalsNASDAQ:SNDXAgios PharmaceuticalsNASDAQ:AGIOSchrödingerNASDAQ:SDGRCatalyst PharmaceuticalsNASDAQ:CPRXStructure TherapeuticsNASDAQ:GPCRView All Competitors PAND Stock Analysis - Frequently Asked Questions How were Pandion Therapeutics' earnings last quarter? Pandion Therapeutics, Inc. (NASDAQ:PAND) posted its quarterly earnings data on Monday, November, 16th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.44) by $0.07. The firm earned $2.63 million during the quarter, compared to analysts' expectations of $1 million. What other stocks do shareholders of Pandion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pandion Therapeutics investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Moderna (MRNA), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Curaleaf (CURLF), Dynavax Technologies (DVAX), Evofem Biosciences (EVFM), OPKO Health (OPK). When did Pandion Therapeutics IPO? Pandion Therapeutics (PAND) raised $94 million in an initial public offering on Friday, July 17th 2020. The company issued 5,500,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley, SVB Leerink and BMO Capital Markets served as the underwriters for the IPO. This page (NASDAQ:PAND) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pandion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
